{"id":48916,"date":"2022-09-28T15:02:57","date_gmt":"2022-09-28T13:02:57","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/"},"modified":"2022-09-28T15:02:57","modified_gmt":"2022-09-28T13:02:57","slug":"sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/","title":{"rendered":"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals"},"content":{"rendered":"
\n

\nInvestment from SK Capital to support Apotex\u2019s next phase of growth and continued innovation for patient affordability<\/i>\n<\/p>\n

<\/a><\/p>\n

NEW YORK–(BUSINESS WIRE)–An affiliate of funds advised by SK Capital Partners, LP (\u201cSK Capital\u201d) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc. (\u201cApotex\u201d or the \u201cCompany\u201d), a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines across all major therapeutic areas for patients around the world.\n<\/p>\n

\n\u201cApotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand. We feel incredibly privileged to have the opportunity to support Apotex with our deep experience in the pharmaceutical sector as it continues to research, develop and produce safe and affordable medicines for patients in Canada, the United States and around the world,\u201d said Aaron Davenport, Managing Director at SK Capital.\n<\/p>\n

\nJeff Watson, President and CEO of Apotex, said, \u201cWe are excited to work with SK Capital, whose industry expertise and resources will help grow our leadership in the market and maintain our focus on improving access to high-quality affordable medicines for millions of patients worldwide.\u201d\n<\/p>\n

\nClosing of the transaction is subject to the satisfaction of customary regulatory conditions.\n<\/p>\n

\nLead arrangers RBC Capital Markets, The Bank of Nova Scotia, HSBC and Truist Securities are providing committed financing in support of the transaction. RBC Capital Markets, Scotiabank, Jefferies LLC and Deutsche Bank Securities Inc. served as financial advisors to SK Capital and Kirkland & Ellis and McMillan LLP served as legal counsel.\n<\/p>\n

\nRothschild & Co served as financial advisor to Apotex and Davies Ward Phillips & Vineberg served as legal counsel.\n<\/p>\n

\nAbout SK Capital
\n
SK Capital is a private investment firm with a disciplined focus on the specialty materials, specialty chemicals, and pharmaceuticals sectors. The firm seeks to build strong and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating, and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth, and profitability, as well as lower operating risk. SK Capital\u2019s portfolio of businesses generates revenues of approximately USD $16 billion annually, employs more than 20,000 people globally and operates 203 plants in 32 countries. The firm currently has approximately USD $6.6 billion of assets under management. For more information, please visit www.skcapitalpartners.com<\/a>.\n<\/p>\n

\nAbout Apotex
\n
Apotex is a proudly Canadian, global pharmaceutical company that produces high-quality, affordable medicines for patients around the world. Apotex employs nearly 8,000 people worldwide in manufacturing, R&D, and commercial operations. Apotex exports to more than 100 countries and territories and operates in more than 45 countries, with a significant presence in Canada, the United States, Mexico, and India. For more information visit: www.apotex.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJeremy Milner
\n
BackBay Communications
\n
jeremy.milner@backbaycommunications.com<\/a>
(401) 862-9422\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Investment from SK Capital to support Apotex\u2019s next phase of growth and continued innovation for patient affordability NEW YORK–(BUSINESS WIRE)–An affiliate of funds advised by SK Capital Partners, LP (\u201cSK Capital\u201d) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc. (\u201cApotex\u201d or the \u201cCompany\u201d), a proudly Canadian, global pharmaceutical company … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48916","6":"format-standard","7":"category-industry"},"yoast_head":"\nSK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Investment from SK Capital to support Apotex\u2019s next phase of growth and continued innovation for patient affordability NEW YORK–(BUSINESS WIRE)–An affiliate of funds advised by SK Capital Partners, LP (\u201cSK Capital\u201d) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc. (\u201cApotex\u201d or the \u201cCompany\u201d), a proudly Canadian, global pharmaceutical company ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-28T13:02:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220928005174\/en\/841488\/21\/SK_Capital_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals\",\"datePublished\":\"2022-09-28T13:02:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/\"},\"wordCount\":480,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005174\\\/en\\\/841488\\\/21\\\/SK_Capital_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/\",\"name\":\"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005174\\\/en\\\/841488\\\/21\\\/SK_Capital_Logo.jpg\",\"datePublished\":\"2022-09-28T13:02:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005174\\\/en\\\/841488\\\/21\\\/SK_Capital_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220928005174\\\/en\\\/841488\\\/21\\\/SK_Capital_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/","og_locale":"en_US","og_type":"article","og_title":"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals - Pharma Trend","og_description":"Investment from SK Capital to support Apotex\u2019s next phase of growth and continued innovation for patient affordability NEW YORK–(BUSINESS WIRE)–An affiliate of funds advised by SK Capital Partners, LP (\u201cSK Capital\u201d) announced today that it has reached an agreement to acquire Apotex Pharmaceutical Holdings Inc. (\u201cApotex\u201d or the \u201cCompany\u201d), a proudly Canadian, global pharmaceutical company ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-28T13:02:57+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220928005174\/en\/841488\/21\/SK_Capital_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals","datePublished":"2022-09-28T13:02:57+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/"},"wordCount":480,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005174\/en\/841488\/21\/SK_Capital_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/","url":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/","name":"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220928005174\/en\/841488\/21\/SK_Capital_Logo.jpg","datePublished":"2022-09-28T13:02:57+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220928005174\/en\/841488\/21\/SK_Capital_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220928005174\/en\/841488\/21\/SK_Capital_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/sk-capital-to-acquire-apotex-a-global-leader-in-affordable-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"SK Capital to Acquire Apotex, a Global Leader in Affordable Pharmaceuticals"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48916","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48916"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48916\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}